{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:40:56Z","timestamp":1777948856050,"version":"3.51.4"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2025-0036_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Ovarian cancer (OC) often presents with peritoneal metastases (PM) which contribute significantly to morbidity and treatment resistance. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) has emerged as a promising modality for locoregional drug delivery in peritoneal surface malignancies. Historically, combined intraperitoneal (IP) and intravenous (IV) cisplatin and paclitaxel regimens have demonstrated activity in first-line OC treatment. PIPAC nab-paclitaxel and cisplatin with systemic nab-paclitaxel holds promise as a safe and effective therapy, but has not been explored in\u00a0OC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0036_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This ongoing, dose de-escalation, single-arm phase I study evaluates triplet bidirectional chemotherapy with a safety lead-in (NCT04329494). The study evaluates the safety and tolerability of a 28-day cycle of Day 1 PIPAC nab-paclitaxel 90\u202fmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and cisplatin 15\u202fmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in combination with Days 8 and 15 IV nab-paclitaxel 100\u202fmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for three cycles in recurrent OC patients with unresectable PM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0036_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Enrollment is ongoing at U.S. academic centers. The primary endpoints are dose-limiting toxicities and adverse events. Secondary endpoints include radiographic (RECIST v1.1), histologic, and surgical response, progression-free and overall survival, and post-operative complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0036_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study investigates the safety, feasibility, and preliminary activity of the combination of PIPAC and systemic IV chemotherapy in recurrent OC patients to determine efficacy and safety for a future Phase II\u00a0trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2025-0036","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T12:56:11Z","timestamp":1766321771000},"page":"39-48","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress"],"prefix":"10.1515","volume":"11","author":[{"given":"Vinita","family":"Popat","sequence":"first","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[{"name":"Department of Computation and Quantitative Medicine , City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora H.","family":"Ruel","sequence":"additional","affiliation":[{"name":"Department of Computation and Quantitative Medicine , City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Yost","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research , City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pathology , City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research , City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine","family":"Villella","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Northwell Health , New York , NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Whyte","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , Northwell Health , New York , NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L.","family":"Whelan","sequence":"additional","affiliation":[{"name":"Department of Surgery , Northwell Health , New York , NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Eng","sequence":"additional","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raechelle","family":"Tinsley","sequence":"additional","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Synold","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research , City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihae","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Raoof","sequence":"additional","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1855-1989","authenticated-orcid":false,"given":"Thanh Hue","family":"Dellinger","sequence":"additional","affiliation":[{"name":"Department of Surgery , 20220 City of Hope National Medical Center , Duarte , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2026050315471971201_j_pp-2025-0036_ref_001","doi-asserted-by":"crossref","unstructured":"Siegel, RL, Kratzer, TB, Giaquinto, AN, Sung, H, Jemal, A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45, https:\/\/doi.org\/10.3322\/caac.21871.","DOI":"10.3322\/caac.21871"},{"key":"2026050315471971201_j_pp-2025-0036_ref_002","doi-asserted-by":"crossref","unstructured":"Torre, LA, Trabert, B, DeSantis, CE, Miller, KD, Samimi, G, Runowicz, CD, et al.. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","DOI":"10.3322\/caac.21456"},{"key":"2026050315471971201_j_pp-2025-0036_ref_003","doi-asserted-by":"crossref","unstructured":"de Bree, E, Michelakis, D, Stamatiou, D, Romanos, J, Zoras, O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum 2017;2:47\u201362. https:\/\/doi.org\/10.1515\/pp-2017-0010.","DOI":"10.1515\/pp-2017-0010"},{"key":"2026050315471971201_j_pp-2025-0036_ref_004","doi-asserted-by":"crossref","unstructured":"Rietveld, PCS, Guchelaar, NAD, Sassen, SDT, Koch, BCP, Mathijssen, RHJ, Koolen, SLW. A clinical pharmacological perspective on intraperitoneal chemotherapy. Drugs 2025;85:931\u201343. https:\/\/doi.org\/10.1007\/s40265-025-02195-9.","DOI":"10.1007\/s40265-025-02195-9"},{"key":"2026050315471971201_j_pp-2025-0036_ref_005","doi-asserted-by":"crossref","unstructured":"Cristea, MC, Frankel, P, Synold, T, Rivkin, S, Lim, D, Chung, V, et al.. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol 2019;83:589\u201398. https:\/\/doi.org\/10.1007\/s00280-019-03767-9.","DOI":"10.1007\/s00280-019-03767-9"},{"key":"2026050315471971201_j_pp-2025-0036_ref_006","doi-asserted-by":"crossref","unstructured":"van Driel, WJ, Koole, SN, Sikorska, K, Schagen van Leeuwen, JH, Schreuder, HWR, Hermans, RHM, et al.. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N\u00a0Engl J Med 2018;378:230\u201340. https:\/\/doi.org\/10.1056\/nejmoa1708618.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2026050315471971201_j_pp-2025-0036_ref_007","doi-asserted-by":"crossref","unstructured":"Solass, W, Kerb, R, Murdter, T, Giger-Pabst, U, Strumberg, D, Tempfer, C, et al.. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2026050315471971201_j_pp-2025-0036_ref_008","doi-asserted-by":"crossref","unstructured":"Eveno, C, Haidara, A, Ali, I, Pimpie, C, Mirshahi, M, Pocard, M. Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy. Pleura Peritoneum 2017;2:103\u20139. https:\/\/doi.org\/10.1515\/pp-2017-0015.","DOI":"10.1515\/pp-2017-0015"},{"key":"2026050315471971201_j_pp-2025-0036_ref_009","doi-asserted-by":"crossref","unstructured":"Nadiradze, G, Horvath, P, Sautkin, Y, Archid, R, Weinreich, FJ, Konigsrainer, A, et al.. Overcoming drug resistance by taking advantage of physical principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers (Basel) 2019;12. https:\/\/doi.org\/10.3390\/cancers12010034.","DOI":"10.3390\/cancers12010034"},{"key":"2026050315471971201_j_pp-2025-0036_ref_010","doi-asserted-by":"crossref","unstructured":"Di Giorgio, A, Macri, A, Ferracci, F, Robella, M, Visaloco, M, De Manzoni, G, et al.. 10\u00a0years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers (Basel) 2023;15. https:\/\/doi.org\/10.3390\/cancers15041125.","DOI":"10.3390\/cancers15041125"},{"key":"2026050315471971201_j_pp-2025-0036_ref_011","doi-asserted-by":"crossref","unstructured":"Pavone, M, Jochum, F, Lecointre, L, Bizzarri, N, Taliento, C, Restaino, S, et al.. Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in ovarian cancer: a systematic review of current evidence. Arch Gynecol Obstet 2024;310:1845\u201356. https:\/\/doi.org\/10.1007\/s00404-024-07586-z.","DOI":"10.1007\/s00404-024-07586-z"},{"key":"2026050315471971201_j_pp-2025-0036_ref_012","doi-asserted-by":"crossref","unstructured":"Taliento, C, Restaino, S, Scutiero, G, Arcieri, M, Bernardi, G, Martinello, R, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: a systematic review. Eur J Surg Oncol 2023;49:107250. https:\/\/doi.org\/10.1016\/j.ejso.2023.107250.","DOI":"10.1016\/j.ejso.2023.107250"},{"key":"2026050315471971201_j_pp-2025-0036_ref_013","doi-asserted-by":"crossref","unstructured":"Moore, KN, Angelergues, A, Konecny, GE, Garcia, Y, Banerjee, S, Lorusso, D, et al.. Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer. N\u00a0Engl J Med 2023;389:2162\u201374. https:\/\/doi.org\/10.1056\/nejmoa2309169.","DOI":"10.1056\/NEJMoa2309169"},{"key":"2026050315471971201_j_pp-2025-0036_ref_014","unstructured":"Pfisterer, J, Shannon, CM, Baumann, K, Rau, J, Harter, P, Joly, F, et al.. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21:699\u2013709. https:\/\/doi.org\/10.1016\/s1470-2045-20-30142-x."},{"key":"2026050315471971201_j_pp-2025-0036_ref_015","doi-asserted-by":"crossref","unstructured":"Vizzielli, G, Giudice, MT, Nardelli, F, Costantini, B, Salutari, V, Inzani, FS, et al.. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (ID: PARROT trial). Ann Surg Oncol 2024;31:1207\u201316. https:\/\/doi.org\/10.1245\/s10434-023-14648-0.","DOI":"10.1245\/s10434-023-14648-0"},{"key":"2026050315471971201_j_pp-2025-0036_ref_016","doi-asserted-by":"crossref","unstructured":"Tempfer, CB, Giger-Pabst, U, Seebacher, V, Petersen, M, Dogan, A, Rezniczek, GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 2018;150:23\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.001.","DOI":"10.1016\/j.ygyno.2018.05.001"},{"key":"2026050315471971201_j_pp-2025-0036_ref_017","doi-asserted-by":"crossref","unstructured":"Blanco, A, Giger-Pabst, U, Solass, W, Zieren, J, Reymond, MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 2013;20:2311\u20136. https:\/\/doi.org\/10.1245\/s10434-012-2840-2.","DOI":"10.1245\/s10434-012-2840-2"},{"key":"2026050315471971201_j_pp-2025-0036_ref_018","doi-asserted-by":"crossref","unstructured":"Tempfer, CB, Celik, I, Solass, W, Buerkle, B, Pabst, UG, Zieren, J, et al.. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol 2014;132:307\u201311. https:\/\/doi.org\/10.1016\/j.ygyno.2013.11.022.","DOI":"10.1016\/j.ygyno.2013.11.022"},{"key":"2026050315471971201_j_pp-2025-0036_ref_019","doi-asserted-by":"crossref","unstructured":"Bakrin, N, Tempfer, C, Scambia, G, De Simone, M, Gabriel, B, Grischke, EM, et al.. PIPAC-OV3: a multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Pleura Peritoneum 2018;3:20180114. https:\/\/doi.org\/10.1515\/pp-2018-0114.","DOI":"10.1515\/pp-2018-0114"},{"key":"2026050315471971201_j_pp-2025-0036_ref_020","doi-asserted-by":"crossref","unstructured":"Robella, M, De Simone, M, Berchialla, P, Argenziano, M, Borsano, A, Ansari, S, et al.. A phase I dose escalation study of oxaliplatin, cisplatin and doxorubicin applied as PIPAC in patients with peritoneal carcinomatosis. Cancers 2021;13. https:\/\/doi.org\/10.3390\/cancers13051060.","DOI":"10.3390\/cancers13051060"},{"key":"2026050315471971201_j_pp-2025-0036_ref_021","doi-asserted-by":"crossref","unstructured":"Tempfer, CB, Winnekendonk, G, Solass, W, Horvat, R, Giger-Pabst, U, Zieren, J, et al.. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 2015;137:223\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2015.02.009.","DOI":"10.1016\/j.ygyno.2015.02.009"},{"key":"2026050315471971201_j_pp-2025-0036_ref_022","unstructured":"Lyon, HC. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy in women with advanced ovarian cancer 2024. [updated September 15, 2024. Available from: https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT04811703\/pressurized-intraperitoneal-aerosol-chemotherapy-pipac-associated-with-systemic-chemotherapy-in-women-with-advanced-ovarian-cancer."},{"key":"2026050315471971201_j_pp-2025-0036_ref_023","doi-asserted-by":"crossref","unstructured":"Somashekhar, SP, Chandrashekar, RKC, Rajgopal, AK, Fernandes, AM, Shanbhag, E, Rakshit, S, et al.. CRS-HIPEC following neo-adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic chemotherapy in primarily advanced inoperable epithelial ovarian cancer: an ISPSM collaborative study. J\u00a0Clin Oncol 2024;42. https:\/\/doi.org\/10.1200\/jco.2024.42.16-suppl.e17504.","DOI":"10.1200\/JCO.2024.42.16_suppl.e17504"},{"key":"2026050315471971201_j_pp-2025-0036_ref_024","doi-asserted-by":"crossref","unstructured":"Liu, J, Berchuck, A, Backes, FJ, Cohen, J, Grisham, R, Leath, C, et al.. Ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024 featured updates to the NCCN guidelines. J\u00a0Natl Compr Cancer Netw 2024;22:512\u20139. https:\/\/doi.org\/10.6004\/jnccn.2024.0052.","DOI":"10.6004\/jnccn.2024.0052"},{"key":"2026050315471971201_j_pp-2025-0036_ref_025","doi-asserted-by":"crossref","unstructured":"Coleman, RL, Brady, WE, McMeekin, DS, Rose, PG, Soper, JT, Lentz, SS, et al.. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 2011;122:111\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2011.03.036.","DOI":"10.1016\/j.ygyno.2011.03.036"},{"key":"2026050315471971201_j_pp-2025-0036_ref_026","doi-asserted-by":"crossref","unstructured":"Chen, N, Brachmann, C, Liu, X, Pierce, DW, Dey, J, Kerwin, WS, et al.. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol 2015;76:699\u2013712. https:\/\/doi.org\/10.1007\/s00280-015-2833-5.","DOI":"10.1007\/s00280-015-2833-5"},{"key":"2026050315471971201_j_pp-2025-0036_ref_027","doi-asserted-by":"crossref","unstructured":"Desai, N, Trieu, V, Yao, Z, Louie, L, Ci, S, Yang, A, et al.. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317\u201324. https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-1634.","DOI":"10.1158\/1078-0432.CCR-05-1634"},{"key":"2026050315471971201_j_pp-2025-0036_ref_028","doi-asserted-by":"crossref","unstructured":"Ceelen, W, Sandra, L, de Sande, LV, Graversen, M, Mortensen, MB, Vermeulen, A, et al.. Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases. EBioMedicine 2022;82:104151. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104151.","DOI":"10.1016\/j.ebiom.2022.104151"},{"key":"2026050315471971201_j_pp-2025-0036_ref_029","doi-asserted-by":"crossref","unstructured":"Lang, N, Diciola, A, Labidi-Galy, I, Ris, F, Di Marco, M, Mach, N, et al.. Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol\u00a0chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. BMJ Open 2023;13:e067691. https:\/\/doi.org\/10.1136\/bmjopen-2022-067691.","DOI":"10.1136\/bmjopen-2022-067691"},{"key":"2026050315471971201_j_pp-2025-0036_ref_030","doi-asserted-by":"crossref","unstructured":"Somashekhar, SP, Kumar, R, Rauthan, A, Patil, P, Kapoor, P, Rakshit, S, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer: interim analysis of Indian randomized control trial. J\u00a0Clin Oncol 2022;40. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.5524.","DOI":"10.1200\/JCO.2022.40.16_suppl.5524"},{"key":"2026050315471971201_j_pp-2025-0036_ref_031","doi-asserted-by":"crossref","unstructured":"Kusamura, S, Azmi, N, Fumagalli, L, Baratti, D, Guaglio, M, Cavalleri, A, et al.. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). Eur J Surg Oncol 2021;47:82\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.022.","DOI":"10.1016\/j.ejso.2019.06.022"},{"key":"2026050315471971201_j_pp-2025-0036_ref_032","doi-asserted-by":"crossref","unstructured":"Schellens, JH, Ma, J, Planting, AS, van der Burg, ME, van Meerten, E, de Boer-Dennert, M, et al.. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996;73:1569\u201375. https:\/\/doi.org\/10.1038\/bjc.1996.296.","DOI":"10.1038\/bjc.1996.296"},{"key":"2026050315471971201_j_pp-2025-0036_ref_033","doi-asserted-by":"crossref","unstructured":"Armstrong, DK, Bundy, B, Wenzel, L, Huang, HQ, Baergen, R, Lele, S, et al.. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N\u00a0Engl J Med 2006;354:34\u201343. https:\/\/doi.org\/10.1056\/nejmoa052985.","DOI":"10.1056\/NEJMoa052985"},{"key":"2026050315471971201_j_pp-2025-0036_ref_034","doi-asserted-by":"crossref","unstructured":"Chan, AW, Tetzlaff, JM, G\u00f8tzsche, PC, Altman, DG, Mann, H, Berlin, JA, et al.. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Br Med J 2013;346:e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","DOI":"10.1136\/bmj.e7586"},{"key":"2026050315471971201_j_pp-2025-0036_ref_035","doi-asserted-by":"crossref","unstructured":"Raoof, M, Malhotra, G, Kohut, A, O\u2019Leary, M, Frankel, P, Tran, T, et al.. PIPAC for the treatment of gynecologic and gastrointestinal peritoneal metastases: technical and logistic considerations of a phase 1 trial. Ann Surg Oncol 2022;29:175\u201385. https:\/\/doi.org\/10.1245\/s10434-021-10505-0.","DOI":"10.1245\/s10434-021-10505-0"},{"key":"2026050315471971201_j_pp-2025-0036_ref_036","doi-asserted-by":"crossref","unstructured":"Frankel, PH, Chung, V, Tuscano, J, Siddiqi, T, Sampath, S, Longmate, J, et al.. Model of a queuing approach for patient accrual in phase 1 oncology studies. JAMA Netw Open 2020;3:e204787. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.4787.","DOI":"10.1001\/jamanetworkopen.2020.4787"},{"key":"2026050315471971201_j_pp-2025-0036_ref_037","doi-asserted-by":"crossref","unstructured":"Clavien, PA, Barkun, J, de Oliveira, ML, Vauthey, JN, Dindo, D, Schulick, RD, et al.. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187\u201396. https:\/\/doi.org\/10.1097\/sla.0b013e3181b13ca2.","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"2026050315471971201_j_pp-2025-0036_ref_038","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine, E, Hilpert, F, Weber, B, Reuss, A, Poveda, A, Kristensen, G, et al.. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J\u00a0Clin Oncol 2014;32:1302\u20138. https:\/\/doi.org\/10.1200\/jco.2013.51.4489.","DOI":"10.1200\/JCO.2013.51.4489"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0036\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:00:19Z","timestamp":1777842019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0036\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2026,3,19]]}},"alternative-id":["10.1515\/pp-2025-0036"],"URL":"https:\/\/doi.org\/10.1515\/pp-2025-0036","relation":{},"ISSN":["2364-7671","2364-768X"],"issn-type":[{"value":"2364-7671","type":"print"},{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}